Meta-analysis: Efficacy and safety of fibroblast growth factor 21 analogues for the treatment of non-alcoholic steatohepatitis and non-alcoholic steatohepatitis-related fibrosis.
Rutao LinJianghua ZhouQinmei SunXin XinYiyang HuMing-Hua ZhengQin FengPublished in: Alimentary pharmacology & therapeutics (2024)
FGF21 analogues appear as promising agents for the treatment of NASH and NASH-related fibrosis, and they generally seem to be safe and well tolerated.